|
Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda. |
|
|
Consulting or Advisory Role - Janssen; Prothena |
Research Funding - Janssen; Karyopharm Therapeutics; Prothena; Takeda |
|
|
Honoraria - Pharmacyclics |
Consulting or Advisory Role - Amgen; Janssen; Prothena; Takeda |
|
|
Honoraria - Alnylam; GlaxoSmithKline; ION Pharma; Pfizer; Prothena |
Consulting or Advisory Role - Alnylam; GlaxoSmithKline; ION Pharma; Pfizer; Prothena |
Research Funding - Alnylam; GlaxoSmithKline; Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; Janssen; Prothena; Seagen; Takeda |
Research Funding - Celgene (Inst) |
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Servier; Takeda |
Research Funding - Celgene |
|
|
Research Funding - Janssen; Prothena |
Travel, Accommodations, Expenses - Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
Honoraria - Cilag; Janssen; Prothena |
Consulting or Advisory Role - Cilag; Janssen |
Research Funding - Prothena |
Travel, Accommodations, Expenses - Celgene; Prothena |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Genmab |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
Travel, Accommodations, Expenses - Janssen; Prothena |